Cassian Yee

Director, Department of Solid Tumor Cell Therapy · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

ImpACT: Improving Treatment Strategies for Anaplastic Thyroid Cancer Through Integration of Novel Therapies and Assessment of Tumor Response
National Cancer Institute · P01
Project lead · $497.8K · University of Tx Md Anderson Can Ctr
2026–2031
MD Anderson Sarcoma SPORE
National Cancer Institute · P50
Project lead · $698.4K · University of Tx Md Anderson Can Ctr
2025–2030
HORMAD-Specific TGF-Beta Resistant Memory T Cells for Treatment of Patients with Gastro-Esophageal Cancer
National Cancer Institute · UH3
Contact PI · $2.3M · University of Tx Md Anderson Can Ctr
2023–2029
Immunotherapy of Uveal Melanoma Using PRAME Vaccine in Combination with Adoptive T Cell Therapy
National Cancer Institute · R01
Contact PI · $886.2K · University of Tx Md Anderson Can Ctr
2022–2028

Adoptive Therapy Using Antigen-Specific CD4 T-Cells
Principal investigator · Withdrawn · Phase 1
M.D. Anderson Cancer Center
2016
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma
Principal investigator · Terminated · Phase 1
Fred Hutchinson Cancer Center
2010
Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma
Principal investigator · Completed · Phase 1, Phase 2
Fred Hutchinson Cancer Center
2007–2012
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma
Principal investigator · Completed · Phase 1
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
2006–2012